Table 1: ABCG2 expression and characteristics of patients.

ABCG2 Expression -value
Positive ( )Negative ( )

Age
 >5014 (66.7%)7 (70%)0.992
 ≤507 (33.3%)3 (30%)
Gender
 Male20 (95.2%)6 (60%)0.027
 Female1 (4.8%)4 (40%)
HBsAg
 Positive14 (66.7%)7 (70%)0.992
 Negative7 (33.3%)3 (30%)
AFP (ng/mL)
 ≤208 (38.1%)2 (20%)0.420
 >2013 (61.9%)8 (80%)
TNM
 I/II15 (71.4%)7 (70%)1.000
 III/IV6 (28.6%)3 (30%)
BCLC
 0/A10 (47.6%)7 (70%)0.280
 B/C/D11 (52.4%)3 (30%)
Differentiation
 Poor3 (16.7%)1 (10%)1.000
 Moderate-Well18 (83.3%)9 (90%)
Tumor number
 Single17 (81.0%)8 (80%)1.000
 Multiple4 (19.0%)2 (20%)
Tumor size
 <59 (42.9%)5 (50%)1.000
 ≥512 (57.1%)5 (50%)
Microvascular invasion
 Present8 (38.1%)3 (30%)0.996
 Absent13 (61.9%)7 (70%)
Macrovascular invasion
 Present6 (28.6%)1 (10%)0.379
 Absent15 (71.4%)9 (90%)
Milan
 In8 (38.1%)5 (50%)0.700
 Out13 (61.9%)5 (50%)
Ki67
 ≤20%9 (42.9%)6 (60%)0.458
 >20%12 (57.1%)4 (40%)

AFP: α-fetoprotein; TNM: TNM staging system of the International Union Against Cancer; BCLC: Barcelona Clinic Liver Cancer staging system; Milan: Milan criteria.